Last reviewed · How we verify
Polichem S.A. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
7 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| P-3073 | P-3073 | phase 3 | PI3K delta inhibitor | PI3K delta | Immunology | |
| P-3058 10% | P-3058 10% | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| P-3058 | P-3058 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| P-3074 | P-3074 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| vehicle of P-3058 10% | vehicle of P-3058 10% | phase 3 | ||||
| P-3074 Vehicle | P-3074 Vehicle | phase 3 | ||||
| amorolfine 5% | amorolfine 5% | phase 3 | Antifungal | Lanosterol 14α-demethylase | Dermatology |
Therapeutic area mix
- Diabetes · 3
- Dermatology · 1
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 2 shared drug classes
- Addpharma Inc. · 2 shared drug classes
- Astellas Pharma Inc · 2 shared drug classes
- AstraZeneca · 2 shared drug classes
- Novartis · 2 shared drug classes
- Shandong New Time Pharmaceutical Co., LTD · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Polichem S.A.:
- Polichem S.A. pipeline updates — RSS
- Polichem S.A. pipeline updates — Atom
- Polichem S.A. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Polichem S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/polichem-s-a. Accessed 2026-06-10.